Rep. Bob Latta Discusses FDA Sunscreen Innovation and OTC Drug User Fee Program

Over-the-Counter (OTC) Drug User Fee Program (AMUFA)

• 💡 The Over-the-Counter (OTC) monograph drug user fee program (AMUFA) is critical for public health, workforce, rural health, and access to affordable medicines.
• ✅ Five years ago, legislation modernized the FDA's regulation of OTC medicines, making the system more efficient, transparent, and open to innovation.
• 🚀 Rep. Latta is leading the reauthorization of AMUFA, emphasizing its role in reducing healthcare burdens and lowering doctor visits for simple treatments.

Concerns Regarding FDA's Implementation

• ⚠️ Rep. Latta expresses concern that the FDA has not fully adhered to congressional intent regarding data requirements for non-prescription drugs, leading to delays.
• 🔬 He believes the FDA has required superfluous information, hindering innovation and preventing consumers from accessing new and improved products.
• 🎯 The goal is to ensure the FDA requires only studies that answer specific questions, not unnecessary data.

FDA's Efforts and Future Plans

• 💻 The FDA has transitioned from a paper-based rulemaking system to an electronic communication system and provided clear guidance.
• 🤝 Meetings with companies on their programs are occurring, and the FDA is meeting its goals under AMUFA.
• ☀️ The first monograph order for sunscreen has been issued, along with 33 final orders and 5 proposed orders to update safety labeling and allow for innovation in dosage forms (e.g., chewables for children).
• 📈 AMUFA 2 aims to foster innovation by increasing opportunities for interaction between companies and the FDA, clarifying expectations, and improving transparency in fees.

International Comparison and US Leadership

• 🌍 There's a perception that Europe is significantly ahead of the US in sunscreen innovation.
• 🇺🇸 Rep. Latta urges the US to lead in this area and looks forward to working with the FDA to achieve this goal.